RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: A-2
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGCAACTCAATAAGCTAGGTGGGTGGGGGACACTACCCGGGGGTGGTTGGGTGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5684210526315789
Affinity: Kd: 214 ± 82 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013, Bioorg Med Chem Lett ): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: B-1
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGTAACTCAATAAGCTAGGTGGGTGGGGGACACTGCCCGGGGGTGGTTGGGTGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5684210526315789
Affinity: Kd: 111 ± 41 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013, Bioorg Med Chem Lett ): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: B-2
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGCAACTCAATAAGCTAGGTGGGTGGGGGACACTGCCCGGGGGTGGTTGGGTGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5789473684210527
Affinity: Kd: 27 ± 1 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013, Bioorg Med Chem Lett ): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: C-1
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGTAACTCAATAAGCTAGGTGGGTGGGGGACACTATCCGGGGGTGGTTGGGTGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5473684210526316
Affinity: Kd: 20 ± 8 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013, Bioorg Med Chem Lett ): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: C-2
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGTAACTCAATAAGCTAGGTGGGTGGGGGACACTACTCGGGGGTGGTTGGGTGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5473684210526316
Affinity: Kd: 19 ± 1 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013, Bioorg Med Chem Lett ): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: C-3
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGCAACTCAATAAGCTAGGTGGGTGGGGGACACTACTCGGGGGTGGTTGGGTGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5578947368421052
Affinity: Kd: 50 ± 21 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013,Bioorg Med Chem Lett): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: C-4
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGTAACTCAGTAAGCTAGGTGGGTGGGGGACACTATCCGGGGGTGGTTGGGTGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5578947368421052
Affinity: Kd: 141 ± 59 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013,Bioorg Med Chem Lett): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: D-1
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGTAACTCAATAGGCTAGGTGGGTGGGGGACACTACCAGGGGGTGGTTGGGTGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5578947368421052
Affinity: Kd: 195 ± 131 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013, Bioorg Med Chem Lett ): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: E-1
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGCGATGGCGGTGGGTGGGGGACAAATTTGGGGGGCGTTGGGTGTTTGTGGTGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5789473684210527
Affinity: Kd: 64 ± 10 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013,Bioorg Med Chem Lett): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: F-1
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGGGTGGTGGGGAGGGGGTTGCTGGGTCGCGACTAGGAAACTCATGCGGTAAGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5789473684210527
Affinity: Kd: 370 ± 311 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013, Bioorg Med Chem Lett ): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: G-1
Target: Hepatoma HepG2 cells, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGCTCAGAAGCTTGATCCTGTGTTCCGCAATGGCCCTCGATTACTGTCCCTACCACATGAGTTTCCCACATCGACTCGAAGTCGTGCATCTGCA3'
Sequence length: 95
GC content: 0.5263157894736842
Affinity: Kd: 153 ± 52 nM
Pool type: 5'-CAGCTCAGAAGCTTGATCCTGTG-N50-GACTCGAAGTCGTGCATCTGCA-3'
Pool random region: 50
Binding buffer/conditions: D-PBS(+) supplemented with 1 mg/ml bovine serum albumin (BSA); To decrease non-specific binding, the binding buffer was supplemented with 20% FBS and 1 mg/ml BSA after round 6.
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Dection and Therapeutic: " ssDNA aptamers recognizing human hepatoma HepG2 cells were isolated using cell-SELEX. Our previous study reported a new targeted DDS for cancer therapy that delivers titanium dioxide (TiO2) nanoparticles to tumor tissues with subsequent generation of hydroxyl radicals from TiO2 nanoparticles activated by external ultrasound irradiation.34 The construction of the TiO2 nanoparticle–aptamer conjugate will be able to provide sonodynamic cancer therapy with enhanced treatment specificity and efficacy."
Reference (2013, Bioorg Med Chem Lett ): Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C., & Shimizu, N. (2013). Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma. Bioorganic & medicinal chemistry letters, 23(6), 1797–1802. https://doi-org.ezproxy.lib.utexas.edu/10.1016/j.bmcl.2013.01.040
Aptamer: N8
Target: N-glycolylneuraminic acid (Neu5Gc)
Type of nucleic acid: ssDNA
Sequence: 5'CATCTGCAGTGTGGCACCATGTACGCCGCGGTGTACCTCCGCGTGTTACGCTACTTTCTGTGCGTGCGAGCGTGAATTCGC3'
Sequence length: 81
GC content: 0.5925925925925926
Affinity: Kd: 6.68 nM
Pool type: 5′-CATCTGCAGTGTGGCACCATG-N40-CGTGCTGAGCGTGAATTCGC-3′
Pool random region: 40
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " The aptamers selected in this study will provide a novel analytical probe for the development of a biosensor to detect Neu5Gc in tissues and sera from patients with tumors as well as to detect Neu5Gc in animal-derived foods. In addition, the successful aptamer candidate can solve the problem that antibody is difficult to prepare in immunological assays. Thus, the discovery of novel aptamers specific for Neu5Gc is important for developing new methods of detecting Neu5Gc for the diagnosis and prevention of cancer as well as food poisoning."
Reference (2013, Biosens Bioelectron ): Gong, S., Ren, H. L., Tian, R. Y., Lin, C., Hu, P., Li, Y. S., Liu, Z. S., Song, J., Tang, F., Zhou, Y., Li, Z. H., Zhang, Y. Y., & Lu, S. Y. (2013). A novel analytical probe binding to a potential carcinogenic factor of N-glycolylneuraminic acid by SELEX. Biosensors & bioelectronics, 49, 547–554. https://doi.org/10.1016/j.bios.2013.05.024
Aptamer: N14
Target: N-glycolylneuraminic acid (Neu5Gc)
Type of nucleic acid: ssDNA
Sequence: 5'CATCTGCAGTGTGGCACCATGAGGCTCTCGATAAGTATAGACACTGAATTTCGAGGTTCTTCGTGCTGAGCGTGAATTCGC3'
Sequence length: 81
GC content: 0.4938271604938271
Affinity: Kd: 6.13 nM
Pool type: 5′-CATCTGCAGTGTGGCACCATG-N40-CGTGCTGAGCGTGAATTCGC-3′
Pool random region: 40
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " The aptamers selected in this study will provide a novel analytical probe for the development of a biosensor to detect Neu5Gc in tissues and sera from patients with tumors as well as to detect Neu5Gc in animal-derived foods. In addition, the successful aptamer candidate can solve the problem that antibody is difficult to prepare in immunological assays. Thus, the discovery of novel aptamers specific for Neu5Gc is important for developing new methods of detecting Neu5Gc for the diagnosis and prevention of cancer as well as food poisoning."
Reference (2013, Biosens Bioelectron ): Gong, S., Ren, H. L., Tian, R. Y., Lin, C., Hu, P., Li, Y. S., Liu, Z. S., Song, J., Tang, F., Zhou, Y., Li, Z. H., Zhang, Y. Y., & Lu, S. Y. (2013). A novel analytical probe binding to a potential carcinogenic factor of N-glycolylneuraminic acid by SELEX. Biosensors & bioelectronics, 49, 547–554. https://doi.org/10.1016/j.bios.2013.05.024
Aptamer: N17
Target: N-glycolylneuraminic acid (Neu5Gc)
Type of nucleic acid: ssDNA
Sequence: 5'CATCTGCAGTGTGGCACCATGATCGCGCATCCTCGGTCGGCGGAGTCGGTGGTGTGTTCTCGTGCTGAGCGTGAATTCGC3'
Sequence length: 80
GC content: 0.6125
Affinity: Kd: 4.58 nM
Pool type: 5′-CATCTGCAGTGTGGCACCATG-N40-CGTGCTGAGCGTGAATTCGC-3′
Pool random region: 40
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " The aptamers selected in this study will provide a novel analytical probe for the development of a biosensor to detect Neu5Gc in tissues and sera from patients with tumors as well as to detect Neu5Gc in animal-derived foods. In addition, the successful aptamer candidate can solve the problem that antibody is difficult to prepare in immunological assays. Thus, the discovery of novel aptamers specific for Neu5Gc is important for developing new methods of detecting Neu5Gc for the diagnosis and prevention of cancer as well as food poisoning."
Reference (2013, Biosens Bioelectron ): Gong, S., Ren, H. L., Tian, R. Y., Lin, C., Hu, P., Li, Y. S., Liu, Z. S., Song, J., Tang, F., Zhou, Y., Li, Z. H., Zhang, Y. Y., & Lu, S. Y. (2013). A novel analytical probe binding to a potential carcinogenic factor of N-glycolylneuraminic acid by SELEX. Biosensors & bioelectronics, 49, 547–554. https://doi.org/10.1016/j.bios.2013.05.024
Aptamer: N20
Target: N-glycolylneuraminic acid (Neu5Gc)
Type of nucleic acid: ssDNA
Sequence: 5'CATCTGCAGTGTGGCACCATGTCCGTAGTGCTTTGTTTGTTGTGTGCTAGGTAGTGTTCTTCGTGCTGAGCGTGAATTCGC3'
Sequence length: 81
GC content: 0.5061728395061729
Affinity: Kd: 73.3 nM
Pool type: 5′-CATCTGCAGTGTGGCACCATG-N40-CGTGCTGAGCGTGAATTCGC-3′
Pool random region: 40
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " The aptamers selected in this study will provide a novel analytical probe for the development of a biosensor to detect Neu5Gc in tissues and sera from patients with tumors as well as to detect Neu5Gc in animal-derived foods. In addition, the successful aptamer candidate can solve the problem that antibody is difficult to prepare in immunological assays. Thus, the discovery of novel aptamers specific for Neu5Gc is important for developing new methods of detecting Neu5Gc for the diagnosis and prevention of cancer as well as food poisoning."
Reference (2013, Biosens Bioelectron ): Gong, S., Ren, H. L., Tian, R. Y., Lin, C., Hu, P., Li, Y. S., Liu, Z. S., Song, J., Tang, F., Zhou, Y., Li, Z. H., Zhang, Y. Y., & Lu, S. Y. (2013). A novel analytical probe binding to a potential carcinogenic factor of N-glycolylneuraminic acid by SELEX. Biosensors & bioelectronics, 49, 547–554. https://doi.org/10.1016/j.bios.2013.05.024